Applying Glycobiology To Develop Novel Medicines



IHP Therapeutics is developing a novel pipeline of glycan therapeutics targeting immune modulation/ inflammation and infection.  IHP’s clinical-stage compound, IHP-009, is a glycan NCE (New Chemical Entity) with anticoagulant, anti-inflammatory and antiviral activity. Clinical planning is currently underway for dosing hospitalized COVID-19 patients with IHP-009.


To improve and save lives through scientific discovery and development of glycan therapeutics.


Our Team

Rinko Ghosh, MS, MBA


Jocelyn Jackson

Acting CFO

Peggy McLaughlin

VP of Clinical Operations

Gabriel Njikang, PhD

Director of CMC Project Mgmt

John Paderi, PhD

Chief Science Officer

Kate Stuart, PhD

 VP of Program Management

Robert Van Gorp

VP of Strategic Sourcing

Board of Directors

Rinko Ghosh, MS, MBA

Vlad Hogenhuis, MD, MBA

John Paderi, PhD

Clinical and Scientific Advisors

Science Student


IHP Therapeutics is building on nearly a century of clinical and basic science research with glycan-based compounds to create the next generation of glyco-medicines to treat diseases with significant unmet need. We are developing both novel pipeline compounds as well as clinical-stage drugs like IHP-009, a new chemical entity with an established clinical safety profile. Our goal is to translate the therapeutic potential of these glycan compounds into clinically significant benefits for patients.